Subtype
Malignant Glioma
CI-CAN-00003164Explore in graph →
589 active trials3 approved drugs67 evidence items
- NCIt
- C4822
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003164Explore in graph →
Clinical trials
2,053 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (325)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02227901 | Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00024570 | Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 60 | INSYS Therapeutics IncINDUSTRY | 1 | Nov 14, 2014 | clinicaltrials |
| NCT00378235 | Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma | withdrawn | Phase 1 / Phase 2 | 0 | INSYS Therapeutics IncINDUSTRY | 1 | Nov 13, 2014 | clinicaltrials |
| NCT00884416 | Sorafenib in Newly Diagnosed High Grade Glioma | completed | Phase 1 | 17 | University Hospital, GenevaOTHER | 1 | Nov 4, 2014 | clinicaltrials |
| NCT00576641 | Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma | completed | Phase 1 | 22 | Cedars-Sinai Medical CenterOTHER | 1 | Oct 30, 2014 | clinicaltrials |
| NCT00528684 | Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas | completed | Phase 1 | 18 | Oncolytics BiotechINDUSTRY | 1 | Oct 2, 2014 | clinicaltrials |
| NCT00960492 | Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma | completed | Phase 1 | 26 | ExelixisINDUSTRY | 1 | Sep 22, 2014 | clinicaltrials |
| NCT00611728 | Ph I SU011248 + Irinotecan in Treatment of Pts w MG | completed | Phase 1 | 25 | Duke UniversityOTHER | 1 | Jul 21, 2014 | clinicaltrials |
| NCT00609999 | Ph I Dasatinib + Erlotinib in Recurrent MG | completed | Phase 1 | 47 | Duke UniversityOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00612989 | Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM | completed | Phase 1 | 42 | Duke UniversityOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT02055196 | Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00093613 | Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00650923 | Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma | completed | Phase 1 | 61 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00042991 | Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT01403285 | Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma | terminated | Phase 1 | 6 | Immatics Biotechnologies GmbHINDUSTRY | 1 | May 19, 2014 | clinicaltrials |
| NCT00575146 | Ketogenic Diet for Recurrent Glioblastoma(ERGO) | completed | Phase 1 | 20 | University Hospital TuebingenOTHER | 1 | May 2, 2014 | clinicaltrials |
| NCT01854099 | Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens(PERFORMANCE) | withdrawn | Phase 1 | 0 | University of FloridaOTHER | 0 | Jan 14, 2014 | clinicaltrials |
| NCT00919737 | Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 24 | NobelpharmaINDUSTRY | 1 | Oct 30, 2013 | clinicaltrials |
| NCT00610571 | Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | completed | Phase 1 | 62 | Katy PetersOTHER | 1 | Oct 25, 2013 | clinicaltrials |
| NCT00385853 | PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs | completed | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Oct 21, 2013 | clinicaltrials |
| NCT01205334 | Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme(COGLI) | terminated | Phase 1 / Phase 2 | 2 | Baylor College of MedicineOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00762255 | A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma | completed | Phase 1 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 25, 2013 | clinicaltrials |
| NCT00939991 | Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas | completed | Phase 1 / Phase 2 | 48 | Katy PetersOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00612638 | Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas | completed | Phase 1 | 96 | Duke UniversityOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00004262 | Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00650949 | Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma | terminated | Phase 1 / Phase 2 | 20 | Gilead SciencesINDUSTRY | 1 | May 3, 2013 | clinicaltrials |
| NCT00316849 | Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 56 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00704080 | A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas | completed | Phase 1 | 54 | SanofiINDUSTRY | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00045565 | Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 9, 2013 | clinicaltrials |
| NCT00959946 | Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 32 | PfizerINDUSTRY | 6 | Feb 22, 2013 | clinicaltrials |
| NCT00576446 | Surgical Resection With Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients(Gliadel Wafer) | completed | Phase 1 | 35 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00612651 | PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas | completed | Phase 1 | 37 | Duke UniversityOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00613132 | Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG | completed | Phase 1 | 78 | Annick DesjardinsOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00613223 | Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas | completed | Phase 1 | 49 | Annick DesjardinsOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT01269411 | RO4929097 in Treating Patients With Recurrent Invasive Gliomas | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00005856 | Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | terminated | Phase 1 / Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00006773 | Bortezomib in Treating Patients With Recurrent Glioma | terminated | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00110032 | Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors | terminated | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00613054 | Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma | completed | Phase 1 | 27 | Annick DesjardinsOTHER | 1 | Dec 5, 2012 | clinicaltrials |
| NCT00734864 | Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma | withdrawn | Phase 1 | 0 | Annick DesjardinsOTHER | 1 | Nov 21, 2012 | clinicaltrials |
| NCT01043536 | Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults(SIB-IMRT) | completed | Phase 1 | 10 | Centre Georges Francois LeclercOTHER | 1 | Sep 25, 2012 | clinicaltrials |
| NCT00948389 | Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) | terminated | Phase 1 / Phase 2 | 28 | Bristol-Myers SquibbINDUSTRY | 4 | Aug 31, 2012 | clinicaltrials |
| NCT00272870 | Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy | terminated | Phase 1 | 1 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Aug 29, 2012 | clinicaltrials |
| NCT01294735 | Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1) | completed | Phase 1 | 19 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 15, 2012 | clinicaltrials |
| NCT01240460 | Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection | completed | Phase 1 | 40 | SanofiINDUSTRY | 1 | Jul 27, 2012 | clinicaltrials |
| NCT00624728 | Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)(GLIO-TEP) | completed | Phase 1 / Phase 2 | 21 | University Hospital, BordeauxOTHER | 1 | May 4, 2012 | clinicaltrials |
| NCT00132158 | ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors | completed | Phase 1 | 19 | St. Jude Children's Research HospitalOTHER | 1 | Apr 17, 2012 | clinicaltrials |
| NCT01189513 | SCH-900105 in Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 20, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Dec 23, 2014source: clinicaltrials